The company has developed Cyclo G6 laser system for the treatment of a range of glaucoma disease states.
In February this year, the US Food and Drug Administration (FDA) granted 510(k) approval for Cyclo G6 Laser System, to treat patients with multiple stages of glaucoma.
MicroPulse therapy, which will be carried out on Cyclo G6 through the newly-patented MicroPulse P3 probe, is developed to treat patients diagnosed with a range of glaucoma disease states.
MicroPulse is a tissue-sparing laser delivery therapy, which works by electronically chopping the laser emission into trains of microsecond pulses.
The Cyclo G6 system comprises glaucoma-dedicated laser and a family of single use probes, as well as patented MP3 disposable.
Iridex president and CEO William Moore said: "The MicroPulse system for the treatment of glaucoma along with MicroPulse P3 disposable probes underscore our evolving razor, razorblade business model that focuses on the sale of follow-on disposables that address glaucoma at its early, middle and late stages of development.
"It is a safe, cost-effective modality that is also in line with our goal of providing value-based medical technologies."
The company develops and markets laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market.
